Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immunocore Holdings Plc ADR (IMCR)

Immunocore Holdings Plc ADR (IMCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,847,882
  • Shares Outstanding, K 50,530
  • Annual Sales, $ 310,200 K
  • Annual Income, $ -51,090 K
  • EBIT $ -45 M
  • EBITDA $ -41 M
  • 60-Month Beta 0.77
  • Price/Sales 5.90
  • Price/Cash Flow N/A
  • Price/Book 4.61

Options Overview Details

View History
  • Implied Volatility 65.42% (-7.79%)
  • Historical Volatility 39.59%
  • IV Percentile 44%
  • IV Rank 37.89%
  • IV High 99.46% on 11/06/25
  • IV Low 44.66% on 11/26/25
  • Expected Move (DTE 22) 4.59 (12.55%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 6
  • Volume Avg (30-Day) 111
  • Put/Call OI Ratio 0.66
  • Today's Open Interest 3,131
  • Open Int (30-Day) 3,794
  • Expected Range 31.98 to 41.16

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 5
  • High Estimate -0.02
  • Low Estimate -0.77
  • Prior Year -0.47
  • Growth Rate Est. (year over year) +40.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.22 +3.83%
on 12/18/25
40.71 -10.18%
on 12/05/25
-2.12 (-5.48%)
since 11/24/25
3-Month
30.50 +19.90%
on 11/06/25
40.71 -10.18%
on 12/05/25
+2.30 (+6.71%)
since 09/24/25
52-Week
23.15 +57.97%
on 04/09/25
40.71 -10.18%
on 12/05/25
+7.91 (+27.60%)
since 12/24/24

Most Recent Stories

More News
Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Analysts are highlighting several low-priced growth stocks that could double in value, offering investors big upside potential at a reasonable entry point

IMCR : 36.57 (+1.05%)
EQX : 14.60 (-1.95%)
BIRK : 42.45 (-0.56%)
Growth Picks: 3 Low-Cost Stocks That Could Double in Value

Analysts are highlighting several low-priced growth stocks that could double in value, offering investors big upside potential at a reasonable entry point

IMCR : 36.57 (+1.05%)
EQX : 14.60 (-1.95%)
BIRK : 42.45 (-0.56%)
Immunocore Holdings (IMCR) Receives a Buy from H.C. Wainwright

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Immunocore Holdings, with a price target of $100.00. The company’s shares opened today at $31.80.Elevate Your...

IMCR : 36.57 (+1.05%)
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

Puma Biotechnology PBYI reported second-quarter 2025 adjusted earnings of 15 cents per share, which beat the Zacks Consensus Estimate of 11 cents. In the year-ago quarter, the company had incurred an...

IMCR : 36.57 (+1.05%)
EXAS : 101.54 (-0.05%)
PBYI : 5.96 (+0.85%)
CRMD : 12.19 (+1.75%)
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

Mirum Pharmaceuticals MIRM reported a loss of 12 cents per share for the second quarter of 2025, much narrower than the Zacks Consensus Estimate of a loss of 31 cents. The company had incurred a loss...

IMCR : 36.57 (+1.05%)
MIRM : 80.75 (+0.87%)
EXAS : 101.54 (-0.05%)
CRMD : 12.19 (+1.75%)
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

Acadia Pharmaceuticals ACAD reported second-quarter 2025 earnings of 16 cents per share, which beat the Zacks Consensus Estimate of 14 cents. In the year-ago quarter, the company had reported earnings...

IMCR : 36.57 (+1.05%)
ARVN : 12.17 (-0.08%)
CRMD : 12.19 (+1.75%)
ACAD : 27.87 (+0.14%)
Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y

Catalyst Pharmaceuticals CPRX reported adjusted earnings of 68 cents per share for the second quarter of 2025, beating the Zacks Consensus Estimate of 58 cents. The company had recorded adjusted earnings...

IMCR : 36.57 (+1.05%)
ARVN : 12.17 (-0.08%)
CRMD : 12.19 (+1.75%)
CPRX : 24.45 (+0.91%)
ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum

ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of $122 million (up 14%...

IMCR : 36.57 (+1.05%)
CRMD : 12.19 (+1.75%)
ADMA : 19.54 (+0.26%)
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion Therapeutics ESPR incurred a loss of 2 cents per share in the second quarter of 2025, which was much narrower than the Zacks Consensus Estimate of a loss of 17 cents. The company had incurred...

ESPR : 3.95 (+1.80%)
IMCR : 36.57 (+1.05%)
ARVN : 12.17 (-0.08%)
CRMD : 12.19 (+1.75%)
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

Recursion Pharmaceuticals RXRX reported a loss of 41 cents per share in the second quarter of 2025, wider than the Zacks Consensus Estimate of a loss of 35 cents. The company had incurred a loss of 40...

IMCR : 36.57 (+1.05%)
ARVN : 12.17 (-0.08%)
CRMD : 12.19 (+1.75%)
RXRX : 4.40 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Immunocore Holdings plc is a late-stage biotechnology company. It engages in development of a novel class of T cell receptor bispecific immunotherapies designed to treat diseases, including cancer, infectious and autoimmune disease. Immunocore Holdings plc is based in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 39.12
2nd Resistance Point 38.18
1st Resistance Point 37.38
Last Price 36.57
1st Support Level 35.64
2nd Support Level 34.70
3rd Support Level 33.90

See More

52-Week High 40.71
Last Price 36.57
Fibonacci 61.8% 34.00
Fibonacci 50% 31.93
Fibonacci 38.2% 29.86
52-Week Low 23.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar